MK-2206
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
PANCREAS
Conditions
PANCREAS, Neuroendocrine
Trial Timeline
Jul 1, 2010 → Feb 1, 2014
NCT ID
NCT01169649About MK-2206
MK-2206 is a phase 2 stage product being developed by Merck for PANCREAS. The current trial status is completed. This product is registered under clinical trial identifier NCT01169649. Target conditions include PANCREAS, Neuroendocrine.
What happened to similar drugs?
1 of 5 similar drugs in PANCREAS were approved
Approved (1) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01249105 | Phase 2 | Withdrawn |
| NCT01186705 | Phase 2 | Terminated |
| NCT01169649 | Phase 2 | Completed |
| NCT00670488 | Phase 1 | Completed |
Competing Products
20 competing products in PANCREAS